Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics
Abdullah PandorRuth Wong

Abstract

As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures ponatinib (Inclusig®; Incyte Corporation) to submit evidence for the clinical and cost effectiveness for previously treated chronic myeloid leukaemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). This paper focusses on the three phases of CML: the chronic phase (CP), the accelerated phase (AP) and the blast crisis phase (BP). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). This article presents the critical review of the company's submission by the ERG and the outcome of the NICE guidance. Clinical evidence for ponatinib was derived from a phase II, industry-sponsored, single-arm, open-label, multicentre, non-comparative study. Despite the limited evidence and potential for biases, this study demonstrated that ponatinib was likely to be an effective treatment (in terms of major cytogenetic response and major haematological response) with an acceptable safety profile for patients with CML. Given the absence of any head-to...Continue Reading

References

Sep 11, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M van AgthovenC A Uyl-de Groot
Sep 13, 2003·Leukemia·E OlavarriaUNKNOWN Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT)
Jul 15, 2005·Health Technology Assessment : HTA·A M GlennyUNKNOWN International Stroke Trial Collaborative Group
Apr 18, 2006·Current Treatment Options in Oncology·Merat Karbasian EsfahaniPeter H Wiernik
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Jill FerrariTrevor D Prior
Aug 8, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Shelagh M SzaboJorge Cortes
Mar 23, 2011·Journal of Experimental Stroke & Translational Medicine·Scott R Evans
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz
Feb 1, 2010·Therapeutic Advances in Hematology·Jerald P Radich
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.